• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于动态超声的模型预测早期乳腺癌患者对新辅助化疗的反应

Dynamic ultrasound-based modeling predictive of response to neoadjuvant chemotherapy in patients with early breast cancer.

作者信息

Wang Xinyi, Zhang Yuting, Yang Mengting, Wu Nan, Wang Shan, Chen Hong, Zhou Tianyang, Zhang Ying, Wang Xiaolan, Jin Zining, Zheng Ang, Yao Fan, Zhang Dianlong, Jin Feng, Qin Pan, Wang Jia

机构信息

Department of Breast Surgery, Second Affiliated Hospital of Dalian Medical University, No. 467 Zhongshan Road, Shahekou District, Dalian, China.

Faculty of Electronic Information and Electrical Engineering, Dalian University of Technology, Dalian, China.

出版信息

Sci Rep. 2024 Dec 30;14(1):31644. doi: 10.1038/s41598-024-80409-y.

DOI:10.1038/s41598-024-80409-y
PMID:39738182
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11685924/
Abstract

Early prediction of patient responses to neoadjuvant chemotherapy (NACT) is essential for the precision treatment of early breast cancer (EBC). Therefore, this study aims to noninvasively and early predict pathological complete response (pCR). We used dynamic ultrasound (US) imaging changes acquired during NACT, along with clinicopathological features, to create a nomogram and construct a machine learning model. This retrospective study included 304 EBC patients recruited from multiple centers. All enrollees had completed NACT regimens, and underwent US examinations at baseline and at each NACT cycle. We subsequently determined that percentage reduction of tumor maximum diameter from baseline to third cycle of NACT serves to independent predictor for pCR, enabling creation of a nomogram ([Formula: see text]). Our predictive accuracy further improved ([Formula: see text]) by combining dynamic US data and clinicopathological features in a machine learning model. Such models may offer a means of accurately predicting NACT responses in this setting, helping to individualize patient therapy. Our study may provide additional insights into the US-based response prediction by focusing on the dynamic changes of the tumor in the early and full NACT cycle.

摘要

早期预测患者对新辅助化疗(NACT)的反应对于早期乳腺癌(EBC)的精准治疗至关重要。因此,本研究旨在非侵入性地早期预测病理完全缓解(pCR)。我们利用NACT期间获得的动态超声(US)成像变化以及临床病理特征,创建了一个列线图并构建了一个机器学习模型。这项回顾性研究纳入了从多个中心招募的304例EBC患者。所有参与者均完成了NACT方案,并在基线和每个NACT周期接受了超声检查。我们随后确定,从基线到NACT第三个周期肿瘤最大直径的缩小百分比是pCR的独立预测指标,从而能够创建一个列线图([公式:见正文])。通过在机器学习模型中结合动态超声数据和临床病理特征,我们的预测准确性进一步提高([公式:见正文])。此类模型可能提供一种在此情况下准确预测NACT反应的方法,有助于实现患者治疗的个体化。我们的研究可能通过关注肿瘤在NACT早期和整个周期的动态变化,为基于超声的反应预测提供更多见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a82/11685924/66559dbaa9b8/41598_2024_80409_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a82/11685924/ce20bf5e524b/41598_2024_80409_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a82/11685924/77a9e0674bfb/41598_2024_80409_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a82/11685924/f5d5fcde395e/41598_2024_80409_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a82/11685924/fe21e9f4b6d3/41598_2024_80409_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a82/11685924/bc45a5fe5760/41598_2024_80409_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a82/11685924/76a0faa9c61b/41598_2024_80409_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a82/11685924/a231b20aee0e/41598_2024_80409_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a82/11685924/66559dbaa9b8/41598_2024_80409_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a82/11685924/ce20bf5e524b/41598_2024_80409_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a82/11685924/77a9e0674bfb/41598_2024_80409_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a82/11685924/f5d5fcde395e/41598_2024_80409_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a82/11685924/fe21e9f4b6d3/41598_2024_80409_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a82/11685924/bc45a5fe5760/41598_2024_80409_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a82/11685924/76a0faa9c61b/41598_2024_80409_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a82/11685924/a231b20aee0e/41598_2024_80409_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a82/11685924/66559dbaa9b8/41598_2024_80409_Fig8_HTML.jpg

相似文献

1
Dynamic ultrasound-based modeling predictive of response to neoadjuvant chemotherapy in patients with early breast cancer.基于动态超声的模型预测早期乳腺癌患者对新辅助化疗的反应
Sci Rep. 2024 Dec 30;14(1):31644. doi: 10.1038/s41598-024-80409-y.
2
Predicting pathological complete response after neoadjuvant chemotherapy in breast cancer by clinicopathological indicators and ultrasound parameters using a nomogram.基于列线图的临床病理指标及超声参数预测乳腺癌新辅助化疗后的病理完全缓解。
Sci Rep. 2024 Jul 16;14(1):16348. doi: 10.1038/s41598-024-64766-2.
3
Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer using a machine learning approach.使用机器学习方法预测乳腺癌新辅助化疗的病理完全缓解。
Breast Cancer Res. 2024 Oct 29;26(1):148. doi: 10.1186/s13058-024-01905-7.
4
Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients.基于超声的乳腺癌新辅助化疗病理反应预测。
Breast. 2018 Jun;39:19-23. doi: 10.1016/j.breast.2018.02.028. Epub 2018 Mar 7.
5
Predicting the efficacy of neoadjuvant chemotherapy in breast cancer patients based on ultrasound longitudinal temporal depth network fusion model.基于超声纵向时间深度网络融合模型预测乳腺癌患者新辅助化疗的疗效
Breast Cancer Res. 2025 Feb 27;27(1):30. doi: 10.1186/s13058-025-01971-5.
6
Changes in the tumor oxygenation but not in the tumor volume and tumor vascularization reflect early response of breast cancer to neoadjuvant chemotherapy.肿瘤氧合的变化而不是肿瘤体积和肿瘤血管生成的变化反映了乳腺癌对新辅助化疗的早期反应。
Breast Cancer Res. 2023 Jan 30;25(1):12. doi: 10.1186/s13058-023-01607-6.
7
Individualized model for predicting pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: A multicenter study.针对乳腺癌患者新辅助化疗病理完全缓解的个体化预测模型:一项多中心研究。
Front Endocrinol (Lausanne). 2022 Aug 17;13:955250. doi: 10.3389/fendo.2022.955250. eCollection 2022.
8
Predictive value of ultrasound doppler parameters in neoadjuvant chemotherapy response of breast cancer: Prospective comparison with magnetic resonance and mammography.超声多普勒参数在乳腺癌新辅助化疗反应中的预测价值:与磁共振和钼靶的前瞻性比较。
PLoS One. 2024 Jun 4;19(6):e0302527. doi: 10.1371/journal.pone.0302527. eCollection 2024.
9
Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer.用于预测乳腺癌新辅助化疗后残余肿瘤大小及保乳手术成功概率的列线图的开发与验证
Cancer. 2006 Oct 1;107(7):1459-66. doi: 10.1002/cncr.22177.
10
The accuracy of MRI in detecting pathological complete response following neoadjuvant chemotherapy in different breast cancer subtypes.MRI在检测不同乳腺癌亚型新辅助化疗后病理完全缓解情况中的准确性。
Surg Oncol. 2023 Dec;51:102011. doi: 10.1016/j.suronc.2023.102011. Epub 2023 Oct 31.

引用本文的文献

1
Assessing Ultrasound as a Tool for Monitoring Tumor Regression During Chemotherapy: Insights from a Cohort of Breast Cancer Patients.评估超声作为化疗期间监测肿瘤消退的工具:来自一组乳腺癌患者的见解。
Cancers (Basel). 2025 May 11;17(10):1626. doi: 10.3390/cancers17101626.

本文引用的文献

1
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.高危早期 HER2 阴性乳腺癌患者接受新辅助化疗时循环肿瘤 DNA 的临床意义和生物学特性。
Cancer Cell. 2023 Jun 12;41(6):1091-1102.e4. doi: 10.1016/j.ccell.2023.04.008. Epub 2023 May 4.
2
Longitudinal MRI-based fusion novel model predicts pathological complete response in breast cancer treated with neoadjuvant chemotherapy: a multicenter, retrospective study.基于纵向磁共振成像的融合新模型预测新辅助化疗治疗乳腺癌的病理完全缓解:一项多中心回顾性研究。
EClinicalMedicine. 2023 Mar 24;58:101899. doi: 10.1016/j.eclinm.2023.101899. eCollection 2023 Apr.
3
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
术前化疗对可手术乳腺癌女性结局的影响。
J Clin Oncol. 2023 Apr 1;41(10):1795-1808. doi: 10.1200/JCO.22.02571.
4
MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis.MRI评估乳腺癌亚型新辅助化疗后的反应:一项系统评价和荟萃分析。
NPJ Breast Cancer. 2022 Sep 19;8(1):107. doi: 10.1038/s41523-022-00475-1.
5
Multivariable Models Based on Baseline Imaging Features and Clinicopathological Characteristics to Predict Breast Pathologic Response after Neoadjuvant Chemotherapy in Patients with Breast Cancer.基于基线影像特征和临床病理特征的多变量模型预测乳腺癌患者新辅助化疗后的乳腺病理反应
Breast Care (Basel). 2022 Jun;17(3):306-315. doi: 10.1159/000521638. Epub 2021 Dec 23.
6
Early prediction of treatment response to neoadjuvant chemotherapy based on longitudinal ultrasound images of HER2-positive breast cancer patients by Siamese multi-task network: A multicentre, retrospective cohort study.基于连体多任务网络的HER2阳性乳腺癌患者纵向超声图像对新辅助化疗治疗反应的早期预测:一项多中心回顾性队列研究
EClinicalMedicine. 2022 Jul 30;52:101562. doi: 10.1016/j.eclinm.2022.101562. eCollection 2022 Oct.
7
Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.在新辅助治疗期间,乳腺癌患者 ctDNA 的持续存在是肿瘤反应不良的重要预测指标。
Clin Cancer Res. 2022 Feb 15;28(4):697-707. doi: 10.1158/1078-0432.CCR-21-3231.
8
Analysis of mammograms using artificial intelligence to predict response to neoadjuvant chemotherapy in breast cancer patients: proof of concept.利用人工智能分析乳腺 X 光照片预测乳腺癌患者新辅助化疗反应:概念验证。
Eur Radiol. 2022 May;32(5):3131-3141. doi: 10.1007/s00330-021-08306-w. Epub 2021 Oct 15.
9
Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer.新辅助治疗作为治疗个体化的平台:聚焦 HER2 阳性和三阴性乳腺癌。
Cancer Treat Rev. 2021 Jul;98:102222. doi: 10.1016/j.ctrv.2021.102222. Epub 2021 May 12.
10
Chemotherapy de-escalation using an F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.基于 F-FDG-PET 的病理缓解适应性策略进行化疗降阶梯治疗 HER2 阳性早期乳腺癌患者(PHERGain):一项多中心、随机、开放标签、非对照、Ⅱ期临床试验。
Lancet Oncol. 2021 Jun;22(6):858-871. doi: 10.1016/S1470-2045(21)00122-4. Epub 2021 May 18.